News & Updates

In a prespecified secondary analysis of the SELECT trial, long-term treatment with semaglutide allows more patients with prediabetes to regress to normoglycaemia while reducing progression to diabetes in some patients. However, semaglutide does not slow glycaemic progression over time.

Older adults with diabetes and hypertension who regularly take their medications tend to have fewer hospitalizations or visits to the emergency room (ER), reports a study.

Nearly half of dementia cases could be prevented or delayed by addressing 14 modifiable risk factors starting from childhood, including two new risk factors – high LDL-cholesterol (LDL-C) level and untreated vision loss – according to a report of the 2024 Lancet Commission on dementia.

Individuals with obesity who underwent a short-term, low-calorie diet demonstrate a multifaceted body response, including an increased brain connectivity in the limbic‒temporal network (emotion and memory) as well as hormone and eating behaviour changes that seem relevant for recovering the weight lost, a recent study has shown.

A post hoc analysis of the Semaglutide Treatment Effect in People with Obesity (STEP) clinical trials has shown that the treatment effect and safety profile of semaglutide 2.4 mg, compared with placebo, are consistent across racial and ethnic subgroups.

In the EARLY* trial, a 16-week intervention consisting of a 5:2 intermittent fasting meal replacement (5:2 MR) diet trumps two antidiabetic agents in improving glycaemic control and weight loss, as well as BP, TG, and HDL-C** levels in overweight or obese Chinese individuals with newly diagnosed type 2 diabetes (T2D).

Machine learning models can predict patients with new-onset diabetes who are at greater risk for developing pancreatic cancer, a study has shown.